Sanofi
Open
53.13 -0.23
Overview
Share price change
24h
Min
52.97
Max
53.52
Income | 1.7B 2.8B |
|---|---|
Sales | 2.8B 14B |
P/E Sector Avg | 30.71 104.138 |
EPS | 2.25 |
Profit margin | 19.884 |
EBITDA | 2.2B 4.2B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +22.02 upside |
Market Cap | 136B |
|---|---|
Previous open | 53.36 |
Previous close | 53.13 |
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Sanofi Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Sanofi Forecast
Price Target
By TipRanks
22.02% upside
12 Months Forecast
Average 65 USD 22.02%
High 67 USD
Low 63 USD
Based on 3 Wall Street analysts offering 12 month price targets forSanofi - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Sanofi
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
